Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects
Trial details
- Registry ID
- NCT04629703
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as Fostamatinib disodium
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 SubjectsNCT04629703 | Rigel Pharmaceuticals | Phase 3 | Completed | 2022-09-05Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |